# Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Effectiveness and Safety of ZP5-9676 for the Treatment of Soil Transmitted Helminthiasis (STH)

> **NCT06128447** · PHASE3 · RECRUITING · sponsor: **Zero Point Five Therapeutics** · enrollment: 300 (estimated)

## Conditions studied

- Soil-Transmitted Helminthiasis (STH)

## Interventions

- **DRUG:** ZP5-9676 600 mg dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06128447
- **Lead sponsor:** Zero Point Five Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-14
- **Primary completion:** 2026-05-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06128447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06128447, "Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Effectiveness and Safety of ZP5-9676 for the Treatment of Soil Transmitted Helminthiasis (STH)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06128447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*